Why the study?
Does trastuzumab increase the risk of heart failure in patients with metastatic breast cancer?
Population
Patients with metastatic breast cancer
Design
Review
Authors
Loading...
Trastuzumab is associated with significant cardiotoxicity, particularly when combined with anthracyclines, necessitating careful risk-benefit assessment.
Does trastuzumab increase the risk of heart failure in patients with metastatic breast cancer?
Trastuzumab is associated with significant cardiotoxicity, particularly when combined with anthracyclines, necessitating careful risk-benefit assessment.
Feldman et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: